systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»10.38109/2075-082X-2024-2-5-15systhiper-814Research ArticleОБЗОРНАЯ СТАТЬЯREVIEWКонсенсус экспертов Российского медицинского общества по артериальной гипертонии. Артериальная гипертония и приверженность к антигипертензивной терапииRussian Medical Society for Arterial Hypertension expert consensus. Arterial hypertension and adherence to antihypertensive therapyhttps://orcid.org/0000-0002-1576-4877ЧазоваИ. Е.ChazovaI. E.

Ирина Евгеньевна Чазова, д. м. н., профессор, академик РАН, заместитель генерального директора по научно-экспертной работе, руководитель отдела

НИИ кардиологии им. А.Л. Мясникова; отдел гипертонии

121552; ул. Академика Чазова, д. 15 а; Москва

Irina E. Chazova, Dr. Sci. (Med.), Professor, Academican of the RAS, Deputy General Director for Scientific and Expert Work, Head of Department

A.L. Myasnikov Research Institute of Cardiology; Hypertension Department

121552; St. Academician Chazova, 15 a; Moscow

https://orcid.org/0000-0002-7381-7818СолнцеваТ. Д.SolntsevaT. D.

Татьяна Дмитриевна Солнцева, аспирант

НИИ кардиологии им. А.Л. Мясникова; отдел гипертонии

121552; ул. Академика Чазова, д. 15 а; Москва

Tatiana D. Solntseva, postgraduate student

A.L. Myasnikov Research Institute of Cardiology; Hypertension Department

121552; St. Academician Chazova, 15 a; Moscow

tatanasolnceva372@gmail.comhttps://orcid.org/0000-0002-0060-095XСиваковаО. А.SivakovaO. A.

Ольга Анатольевна Сивакова, к. м. н., заведующая отделением

НИИ кардиологии им. А.Л. Мясникова; 5 кардиологическое отделение

121552; ул. Академика Чазова, д. 15 а; Москва

Olga A. Sivakova, Cand. Sci. (Med.)

A.L. Myasnikov Research Institute of Cardiology

121552; St. Academician Chazova, 15 a; Moscow

https://orcid.org/0000-0003-4369-1393АгеевФ. Т.AgeevF. T.

Фаиль Таипович Агеев, д. м. н., профессор, руководитель отдела

НИИ кардиологии им. А.Л. Мясникова; отдел амбулаторных лечебно-диагностических технологий

121552; ул. Академика Чазова, д. 15 а; Москва

Fail T. Ageev, Dr. Sci. (Med.), Professor, Head of Department

A.L. Myasnikov Research Institute of Cardiology; Department Outpatient Treatment and Diagnostic Technologies

121552; St. Academician Chazova, 15 a; Moscow

https://orcid.org/0000-0002-3321-2902ФофановаТ. В.FofanovaT. V.

Татьяна Вениаминовна Фофанова, д. м. н., старший научный сотрудник

НИИ кардиологии им. А.Л. Мясникова; отдел амбулаторных лечебно-диагностических технологий

121552; ул. Академика Чазова, д. 15 а; Москва

Tatiana V. Fofanova, Dr. Sci. (Med.), Senior Researcher

A.L. Myasnikov Research Institute of Cardiology

121552; St. Academician Chazova, 15 a; Moscow

https://orcid.org/0000-0002-2699-1610БрагинаА. Е.BraginaA. E.

Анна Евгеньевна Брагина, д. м. н., профессор

кафедра факультетской терапии № 2

119991;  ул. Трубецкая, д. 8, стр. 2; Москва

Anna E. Bragina, Dr. Sci. (Med.), Professor

Department of Faculty Therapy No 2

119991; Bldg. 8/2, Trubetskaya St.; Moscow

https://orcid.org/0000-0002-5820-1759ТрушинаО. Ю.TrushinaO. Iu.

Ольга Юрьевна Трушина, д. м. н., профессор

Институт клинической медицины им. Н. В. Склифосовского; кафедра факультетской терапии № 1

119991;  ул. Трубецкая, д. 8, стр. 2; Москва

Olga Iu. Trushina, Dr. Sci. (Med.), Professor

N.V. Sklifosovsky Institute of Clinical Medicine; Department of Faculty Therapy No 1

119991; Bldg. 8/2, Trubetskaya St.; Moscow

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр кардиологии имени академика Е.И. Чазова» Минздрава РоссииРоссияE.I. Chazov National Medical Research Center of cardiologyRussian FederationФГАОУ Первый МГМУ им. И.М. Сеченова (Сеченовский Университет) Минздрава РоссииРоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian Federation202425062024212717Copyright © Чазова И.Е., Солнцева Т.Д., Сивакова О.А., Агеев Ф.Т., Фофанова Т.В., Брагина А.Е., Трушина О.Ю., 20242024Чазова И.Е., Солнцева Т.Д., Сивакова О.А., Агеев Ф.Т., Фофанова Т.В., Брагина А.Е., Трушина О.Ю.Chazova I.E., Solntseva T.D., Sivakova O.A., Ageev F.T., Fofanova T.V., Bragina A.E., Trushina O.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/814

   Несмотря на существующие рекомендации по диагностике и лечению артериальной гипертонии (АГ), широкий выбор антигипертензивных препаратов (АГП), эффективность лечения АГ сохраняется на низком уровне. Основной причиной неудовлетворительного контроля АГ является неприверженность пациентов к проводимому лечению, что негативно влияет на прогноз в отношении сердечно-сосудистых осложнений. Первым шагом в алгоритме повышения приверженности к антигипертензивной терапии (АГТ) является определение ее уровня. Существуют различные методы оценки приверженности, отличающиеся доступностью и точностью. Выделяют несколько категорий факторов, влияющих на уровень приверженности. Выявление причин у конкретного больного является значимым этапом на пути преодоления низкой приверженности к АГТ. Кроме того, необходимо использование стратегий по повышению уровня приверженности к АГТ, включающих как «упрощение» схемы лечения, так и укрепление взаимодействия врач-пациент.

   Целью данного консенсуса является обобщение и дополнение знаний о распространённости приверженности к АГТ у пациентов с АГ, методах оценки уровня приверженности, причинах низкой приверженности к лечению артериальной гипертонии, подходах к улучшению приверженности к приёму АГП.

   Despite the existing recommendations for the diagnosis and treatment of arterial hypertension, a wide selection of antihypertensive drugs, the efficacy of treatment of arterial hypertension remains low. The main cause for unsatisfactory control of arterial hypertension is patients’ non-adherence to treatment, which adversely affects the prognosis for cardiovascular complications. The first step in increasing adherence to antihypertensive therapy is to determine its level. There are various methods characterized by their accessibility and accuracy for assessing adherence. There are several categories of factors influencing the level of adherence. Identifying the cause in a subsequent patient is a significant step in reducing adherence to antihypertensive therapy. In addition, it’s necessary to use strategies to increase adherence to antihypertensive therapy, including both “simplification” of the treatment regimen and strengthening the doctor-patient interaction.

   The aim of this consensus is to summarize and supplement knowledge about the prevalence of adherence to antihypertensive therapy in patients with arterial hypertension, methods for assessing the level of adherence, the reasons for low adherence to the treatment of arterial hypertension and approaches to improving adherence to antihypertensive medications.

артериальная гипертензияартериальное давлениеприверженностьантигипертензивная терапияантигипертензивные препаратыпсевдорезистентностьлекарственное средствофиксированная комбинацияпобочные эффектыпрогнозarterial hypertensionblood pressureadherenceantihypertensive therapyantihypertensive medicationpseudoresistancemedicationfixed combinationadverse effectprognosisАвторы декларируют отсутствие внешнего финансирования для проведения исследования и публикации статьиThe authors declare that there is no external funding for the exploration and analysis workReferencesАксенова АВ, Ощепкова ЕВ, Чазова ИЕ. Лечение больных артериальной гипертонией в реальной клинической практике в 2010–2020 гг.(по данным национального регистра артериальной гипертонии). Терапевтический архив 2022;94:9–17. doi: 10.26442/00403660.2022.01.201318Aksenova AV, Oschepkova EV, Chazova IE. Treatment of patients with arterial hypertension in clinical practice in 2010–2020 (according to the national register of hypertension). Terapevticheskii arkhiv 2022;94(1):9-17. (in Russ.) doi: 10.26442/00403660.2022.01.201318Zhou D, Xi B, Zhao M, Wang L, Veeranki SP. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: The NHANES III Linked Mortality Study. Sci Rep 2018;8:1–7. doi: 10.1038/s41598-018-27377-2Zhou D, Xi B, Zhao M, Wang L, Veeranki SP. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: The NHANES III Linked Mortality Study. Sci Rep 2018;8:1–7. doi: 10.1038/s41598-018-27377-2Muntner P, Hardy ST, Fine LJ, et al. Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018. JAMA 2020;324:1190. doi: 10.1001/jama.2020.14545Muntner P, Hardy ST, Fine LJ, et al. Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018. JAMA 2020;324:1190. doi: 10.1001/jama.2020.14545Балабанова Ю.А., Драпкина О.М., Куценко В.А., и др. Артериальная гипертония в российской популяции в период пандемии COVID-19: гендерные различия в распространённости, лечении и его эффективности. Данные исследования ЭССЕ-РФ3. Кардиоваскулярная терапия и профилактика 2023;22:3785. doi: 10.15829/1728-8800-2023-3785Balanova Yu.A., Drapkina O.M., Kutsenko V.A., et al. Hypertension in the Russian population during the COVID-19 pandemic: sex differences in prevalence, treatment and its effectiveness. Data from the ESSE-RF3 study. Cardiovascular Therapy and Prevention. 2023;22(8S):3785. (In Russ.) doi: 10.15829/1728-8800-2023-3785Zhou B, Carrillo-Larco RM, Danaei G, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021;398:957–80. doi: 10.1016/S0140-6736(21)01330-1Zhou B, Carrillo-Larco RM, Danaei G, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021;398:957–80. doi: 10.1016/S0140-6736(21)01330-1Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA. Refractory hypertension: A novel phenotype of antihypertensive treatment failure. Hypertension 2016;67:1085–92. doi: 10.1161/HYPERTENSIONAHA.116.06587Dudenbostel T, Siddiqui M, Oparil S, Calhoun DA. Refractory hypertension: A novel phenotype of antihypertensive treatment failure. Hypertension 2016;67:1085–92. doi: 10.1161/HYPERTENSIONAHA.116.06587Аксенова АВ, Сивакова ОА, Блинова НВ, и др. Консенсус экспертов Российского медицинского общества по артериальной гипертонии по диагностике и лечению резистентной артериальной гипертонии. Терапевтический архив 2021;93:1018–29. doi: 10.26442/00403660.2021.09.201007Aksenova A.V., Sivakova O.A., Blinova N.V., et al. Russian Medical Society for Arterial Hypertension expert consensus. Resistant hypertension: detection and management. Terapevticheskii arkhiv 2021;93(9):1018-1029. (in Russ.) doi: 10.26442/00403660.2021.09.201007Buhnerkempe MG, Botchway A, Prakash V, et al. Prevalence of refractory hypertension in the United States from 1999 to 2014. J Hypertens 2019;37:1797–804. doi: 10.1097/HJH.0000000000002103Buhnerkempe MG, Botchway A, Prakash V, et al. Prevalence of refractory hypertension in the United States from 1999 to 2014. J Hypertens 2019;37:1797–804. doi: 10.1097/HJH.0000000000002103Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012;125:1635–42. doi: 10.1161/CIRCULATIONAHA.111.068064Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012;125:1635–42. doi: 10.1161/CIRCULATIONAHA.111.068064Chia R, Pandey A, Vongpatanasin W. Resistant hypertension-defining the scope of the problem. Prog Cardiovasc Dis 2020;63:46–50. doi: 10.1016/j.pcad.2019.12.006Chia R, Pandey A, Vongpatanasin W. Resistant hypertension-defining the scope of the problem. Prog Cardiovasc Dis 2020;63:46–50. doi: 10.1016/j.pcad.2019.12.006Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertensi. J Hypertens 2023;Publish Ah. doi: 10.1097/HJH.0000000000003480Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertensi. J Hypertens 2023;Publish Ah. doi: 10.1097/HJH.0000000000003480Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: Detection, evaluation, and management a scientific statement from the American Heart Association. vol. 72. 2018. doi: 10.1161/HYP.0000000000000084Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: Detection, evaluation, and management a scientific statement from the American Heart Association. vol. 72. 2018. doi: 10.1161/HYP.0000000000000084Choudhry NK, Kronish IM, Vongpatanasin W, et al. Medication adherence and blood pressure control: a scientific statement from the American Heart Association. Hypertension 2022;79:E1–14. doi: 10.1161/HYP.0000000000000203Choudhry NK, Kronish IM, Vongpatanasin W, et al. Medication adherence and blood pressure control: a scientific statement from the American Heart Association. Hypertension 2022;79:E1–14. doi: 10.1161/HYP.0000000000000203Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997;241:317–25. doi: 10.1046/j.1365-2796.1997.112133000.xInsull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997;241:317–25. doi: 10.1046/j.1365-2796.1997.112133000.xChaudri NA. Adherence to long-term therapies evidence for action World Health Organization (WHO). Ann Saudi Med 2004;24:221–2. doi: 10.5144/0256-4947.2004.221Chaudri NA. Adherence to long-term therapies evidence for action World Health Organization (WHO). Ann Saudi Med 2004;24:221–2. doi: 10.5144/0256-4947.2004.221Bramley TJ, Nightengale BS, Frech-Tamas F, Gerbino PP. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006;12:239–45. doi: 10.18553/jmcp.2006.12.3.239Bramley TJ, Nightengale BS, Frech-Tamas F, Gerbino PP. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 2006;12:239–45. doi: 10.18553/jmcp.2006.12.3.239Dalli LL, Olaiya MT, Kim J, et al. Antihypertensive medication adherence and the risk of vascular events and falls after stroke: a real-world effectiveness study using linked registry data. Hypertension 2023;80:182–91. doi: 10.1161/HYPERTENSIONAHA.122.19883Dalli LL, Olaiya MT, Kim J, et al. Antihypertensive medication adherence and the risk of vascular events and falls after stroke: a real-world effectiveness study using linked registry data. Hypertension 2023;80:182–91. doi: 10.1161/HYPERTENSIONAHA.122.19883Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521–30. doi: 10.1097/01.mlr.0000163641.86870.afSokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521–30. doi: 10.1097/01.mlr.0000163641.86870.afBurnier M, Egan BM. Adherence in hypertension. Circ Res 2019;124:1124–40. doi: 10.1161/CIRCRESAHA.118.313220Burnier M, Egan BM. Adherence in hypertension. Circ Res 2019;124:1124–40. doi: 10.1161/CIRCRESAHA.118.313220Lemstra M, Nwankwo C, Bird Y, Moraros J. Primary nonadherence to chronic disease medications: A meta-analysis. Patient Prefer Adherence 2018;12:721–31. doi: 10.2147/PPA.S161151Lemstra M, Nwankwo C, Bird Y, Moraros J. Primary nonadherence to chronic disease medications: A meta-analysis. Patient Prefer Adherence 2018;12:721–31. doi: 10.2147/PPA.S161151Degli Esposti L, Degli Esposti E, Valpiani G, et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther 2002;24:1347–57. doi: 10.1016/S0149-2918(02)80039-XDegli Esposti L, Degli Esposti E, Valpiani G, et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther 2002;24:1347–57. doi: 10.1016/S0149-2918(02)80039-XGupta P, Patel P, Štrauch B, et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension 2017;69:1113–20. doi: 10.1161/HYPERTENSIONAHA.116.08729Gupta P, Patel P, Štrauch B, et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension 2017;69:1113–20. doi: 10.1161/HYPERTENSIONAHA.116.08729Hameed MA, Tebbit L, Jacques N, et al. Non-adherence to antihypertensive medication is very common among resistant hypertensives: Results of a directly observed therapy clinic. J Hum Hypertens 2016;30:83–9. doi: 10.1038/jhh.2015.38Hameed MA, Tebbit L, Jacques N, et al. Non-adherence to antihypertensive medication is very common among resistant hypertensives: Results of a directly observed therapy clinic. J Hum Hypertens 2016;30:83–9. doi: 10.1038/jhh.2015.38Lauffenburger JC, Landon JE, Fischer MA. Effect of combination therapy on adherence among US patients initiating therapy for hypertension: a cohort study. J Gen Intern Med 2017;32:619–25. doi: 10.1007/s11606-016-3972-zLauffenburger JC, Landon JE, Fischer MA. Effect of combination therapy on adherence among US patients initiating therapy for hypertension: a cohort study. J Gen Intern Med 2017;32:619–25. doi: 10.1007/s11606-016-3972-zTajeu GS, Kent ST, Kronish IM, et al. Trends in antihypertensive medication discontinuation and low adherence among medicare beneficiaries initiating treatment from 2007 to 2012. Hypertension 2016;68:565–75. doi: 10.1161/HYPERTENSIONAHA.116.07720Tajeu GS, Kent ST, Kronish IM, et al. Trends in antihypertensive medication discontinuation and low adherence among medicare beneficiaries initiating treatment from 2007 to 2012. Hypertension 2016;68:565–75. doi: 10.1161/HYPERTENSIONAHA.116.07720Tajeu GS, Kent ST, Huang L, et al. Antihypertensive Medication Nonpersistence and Low Adherence for Adults <65 Years Initiating Treatment in 2007-2014. Hypertension 2019;74:35–46. doi: 10.1161/HYPERTENSIONAHA.118.12495Tajeu GS, Kent ST, Huang L, et al. Antihypertensive Medication Nonpersistence and Low Adherence for Adults <65 Years Initiating Treatment in 2007-2014. Hypertension 2019;74:35–46. doi: 10.1161/HYPERTENSIONAHA.118.12495Feng Y, Zhao Y, Yang X, et al. Adherence to antihypertensive medication and cardiovascular disease events in hypertensive patients: a dose–response meta-analysis of 2 769 700 participants in cohort study. QJM An Int J Med 2022;115:279–86. doi: 10.1093/qjmed/hcaa349Feng Y, Zhao Y, Yang X, et al. Adherence to antihypertensive medication and cardiovascular disease events in hypertensive patients: a dose–response meta-analysis of 2 769 700 participants in cohort study. QJM An Int J Med 2022;115:279–86. doi: 10.1093/qjmed/hcaa349Burnier M. Drug adherence in hypertension. Pharmacol Res 2017;125:142–9. doi: 10.1016/j.phrs.2017.08.015Burnier M. Drug adherence in hypertension. Pharmacol Res 2017;125:142–9. doi: 10.1016/j.phrs.2017.08.015Schoenthaler A, Chaplin WF, Allegrante JP, et al. Provider communication effects medication adherence in hypertensive African Americans. Patient Educ Couns 2009;75:185–91. doi: 10.1016/j.pec.2008.09.018Schoenthaler A, Chaplin WF, Allegrante JP, et al. Provider communication effects medication adherence in hypertensive African Americans. Patient Educ Couns 2009;75:185–91. doi: 10.1016/j.pec.2008.09.018Schoenthaler A, Knafl GJ, Fiscella K, Ogedegbe G. Addressing the social needs of hypertensive patients. Circ Cardiovasc Qual Outcomes 2017;10:e003659. doi: 10.1161/CIRCOUTCOMES.117.003659Schoenthaler A, Knafl GJ, Fiscella K, Ogedegbe G. Addressing the social needs of hypertensive patients. Circ Cardiovasc Qual Outcomes 2017;10:e003659. doi: 10.1161/CIRCOUTCOMES.117.003659Ali DH, Kiliç B, Hart HE, et al. Therapeutic inertia in the management of hypertension in primary care. J Hypertens 2021;39:1238–45. doi: 10.1097/HJH.0000000000002783Ali DH, Kiliç B, Hart HE, et al. Therapeutic inertia in the management of hypertension in primary care. J Hypertens 2021;39:1238–45. doi: 10.1097/HJH.0000000000002783Rea F, Corrao G, Merlino L, Mancia G. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension 2018;72:846–53. doi: 10.1161/HYPERTENSIONAHA.118.11308Rea F, Corrao G, Merlino L, Mancia G. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension 2018;72:846–53. doi: 10.1161/HYPERTENSIONAHA.118.11308Guthrie B, Inkster M, Fahey T. Tackling therapeutic inertia: role of treatment data in quality indicators. BMJ 2007;335:542–4. doi: 10.1136/bmj.39259.400069.ADGuthrie B, Inkster M, Fahey T. Tackling therapeutic inertia: role of treatment data in quality indicators. BMJ 2007;335:542–4. doi: 10.1136/bmj.39259.400069.ADProia KK, Thota AB, Njie GJ, et al. Team-Based care and improved blood pressure control. Am J Prev Med 2014;47:86–99. doi: 10.1016/j.amepre.2014.03.004Proia KK, Thota AB, Njie GJ, et al. Team-Based care and improved blood pressure control. Am J Prev Med 2014;47:86–99. doi: 10.1016/j.amepre.2014.03.004Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012;59:1124–31. doi: 10.1161/HYPERTENSIONAHA.112.194167Egan BM, Bandyopadhyay D, Shaftman SR, et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012;59:1124–31. doi: 10.1161/HYPERTENSIONAHA.112.194167Poulter NR, Borghi C, Parati G, et al. Medication adherence in hypertension. J Hypertens 2020;38:579–87. doi: 10.1097/HJH.0000000000002294Poulter NR, Borghi C, Parati G, et al. Medication adherence in hypertension. J Hypertens 2020;38:579–87. doi: 10.1097/HJH.0000000000002294Christensen DB, Williams B, Goldberg HI, et al. Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med Care 1997;35:1164–70. doi: 10.1097/00005650-199711000-00008Christensen DB, Williams B, Goldberg HI, et al. Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med Care 1997;35:1164–70. doi: 10.1097/00005650-199711000-00008Солнцева Т.Д., Сивакова О.А., Аксёнова А.В., Чазова И.Е. Антигипертензивная терапия и приверженность к лечению у пациентов с неконтролируемой артериальной гипертонией. Евразийский кардиологический журнал 2023;1685:24–30. doi: 10.38109/2225-1685-2023-4-24-30Solntseva T.D., Sivakova O.A., Aksenova A.V., Chazova I.E. Antihypertensive therapy and medication adherence in patients with uncontrolled arterial hypertension. Eurasian heart journal. 2023;(4):24-30. (In Russ.) doi: 10.38109/2225-1685-2023-4-24-30Xie L., Frech-Tamas F., Marrett E., Baser O. A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy. Curr Med Res Opin 2014;30:2415–22. doi: 10.1185/03007995.2014.964853Xie L., Frech-Tamas F., Marrett E., Baser O. A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy. Curr Med Res Opin 2014;30:2415–22. doi: 10.1185/03007995.2014.964853Jackson T, Wright J, Jeff D. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103–16. doi: 10.1056/NEJMoa1511939Jackson T, Wright J, Jeff D. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103–16. doi: 10.1056/NEJMoa1511939Dusing R, Weisser B, Mengden T. Changes in antihypertensive therapy – the role of adverse effects and compliance. Blood Press 1998;7:313–5. doi: 10.1080/080370598437187Dusing R, Weisser B, Mengden T. Changes in antihypertensive therapy – the role of adverse effects and compliance. Blood Press 1998;7:313–5. doi: 10.1080/080370598437187Chambers JA, O’Carroll RE, Dennis M, et al. “My doctor has changed my pills without telling me”: impact of generic medication switches in stroke survivors. J Behav Med 2014;37:890–901. doi: 10.1007/s10865-013-9550-5Chambers JA, O’Carroll RE, Dennis M, et al. “My doctor has changed my pills without telling me”: impact of generic medication switches in stroke survivors. J Behav Med 2014;37:890–901. doi: 10.1007/s10865-013-9550-5Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728–40. doi: 10.18553/jmcp.2009.15.9.728Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728–40. doi: 10.18553/jmcp.2009.15.9.728Gebreyohannes EA, Bhagavathula AS, Abebe TB, et al. Adverse effects and non-adherence to antihypertensive medications in University of Gondar Comprehensive Specialized Hospital. Clin Hypertens 2019;25:1. doi: 10.1186/s40885-018-0104-6Gebreyohannes EA, Bhagavathula AS, Abebe TB, et al. Adverse effects and non-adherence to antihypertensive medications in University of Gondar Comprehensive Specialized Hospital. Clin Hypertens 2019;25:1. doi: 10.1186/s40885-018-0104-6Mancia G, Parodi A, Merlino L, Corrao G. Heterogeneity in antihypertensive treatment discontinuation between drugs belonging to the same class. J Hypertens 2011;29:1012–8. doi: 10.1097/HJH.0b013e32834550d0Mancia G, Parodi A, Merlino L, Corrao G. Heterogeneity in antihypertensive treatment discontinuation between drugs belonging to the same class. J Hypertens 2011;29:1012–8. doi: 10.1097/HJH.0b013e32834550d0Jeong SM, Kim S, Wook Shin D, et al. Persistence and adherence to antihypertensive drugs in newly treated hypertensive patients according to initial prescription. Eur J Prev Cardiol 2021;28:E1–4. doi: 10.1177/2047487319900326Jeong SM, Kim S, Wook Shin D, et al. Persistence and adherence to antihypertensive drugs in newly treated hypertensive patients according to initial prescription. Eur J Prev Cardiol 2021;28:E1–4. doi: 10.1177/2047487319900326Corrao G, Soranna D, Merlino L, Mancia G. Similarity between generic and brand‐name antihypertensive drugs for primary prevention of cardiovascular disease: evidence from a large population‐based study. Eur J Clin Invest 2014;44:933–9. doi: 10.1111/eci.12326Corrao G, Soranna D, Merlino L, Mancia G. Similarity between generic and brand‐name antihypertensive drugs for primary prevention of cardiovascular disease: evidence from a large population‐based study. Eur J Clin Invest 2014;44:933–9. doi: 10.1111/eci.12326Lee H, Yano Y, Cho SMJ, H et al. Adherence to antihypertensive medication and incident cardiovascular events in young adults with hypertension. Hypertension 2021;77:1341–9. doi: 10.1161/HYPERTENSIONAHA.120.16784Lee H, Yano Y, Cho SMJ, H et al. Adherence to antihypertensive medication and incident cardiovascular events in young adults with hypertension. Hypertension 2021;77:1341–9. doi: 10.1161/HYPERTENSIONAHA.120.16784Hamrahian SM, Maarouf OH, Fülöp T. A critical review of medication adherence in hypertension: barriers and facilitators clinicians should consider. Patient Prefer Adherence 2022;16:2749–57. doi: 10.2147/PPA.S368784Hamrahian SM, Maarouf OH, Fülöp T. A critical review of medication adherence in hypertension: barriers and facilitators clinicians should consider. Patient Prefer Adherence 2022;16:2749–57. doi: 10.2147/PPA.S368784Simpson J, Jackson CE, Haig C, Jhund PS, Tomaszewski M, Gardner RS, и др. Adherence to prescribed medications in patients with heart failure: insights from liquid chromatography–tandem mass spectrometry-based urine analysis. Eur Hear J – Cardiovasc Pharmacother 2021;7:296–301. doi: 10.1093/ehjcvp/pvaa071Simpson J, Jackson CE, Haig C, Jhund PS, Tomaszewski M, Gardner RS, и др. Adherence to prescribed medications in patients with heart failure: insights from liquid chromatography–tandem mass spectrometry-based urine analysis. Eur Hear J – Cardiovasc Pharmacother 2021;7:296–301. doi: 10.1093/ehjcvp/pvaa071Morrison VL, Holmes EAF, Parveen S, et al. Predictors of self-reported adherence to antihypertensive medicines: a multinational, cross-sectional survey. Value Heal 2015;18:206–16. doi: 10.1016/j.jval.2014.12.013Morrison VL, Holmes EAF, Parveen S, et al. Predictors of self-reported adherence to antihypertensive medicines: a multinational, cross-sectional survey. Value Heal 2015;18:206–16. doi: 10.1016/j.jval.2014.12.013Mancia G, Zambon A, Soranna D, et al. Factors involved in the discontinuation of antihypertensive drug therapy. J Hypertens 2014;32:1708–16. doi: 10.1097/HJH.0000000000000222Mancia G, Zambon A, Soranna D, et al. Factors involved in the discontinuation of antihypertensive drug therapy. J Hypertens 2014;32:1708–16. doi: 10.1097/HJH.0000000000000222Delara M, Murray L, Jafari B, et al. Prevalence and factors associated with polypharmacy : a systematic review and meta-analysis. BMC Geriatr 2022;22:601. doi: 10.1186/s12877-022-03279-xDelara M, Murray L, Jafari B, et al. Prevalence and factors associated with polypharmacy : a systematic review and meta-analysis. BMC Geriatr 2022;22:601. doi: 10.1186/s12877-022-03279-xEze-Nliam CM, Thombs BD, Lima BB, et al. The association of depression with adherence to antihypertensive medications : a systematic review. J Hypertens 2010;28:1785–95. doi: 10.1097/HJH.0b013e32833b4a6fEze-Nliam CM, Thombs BD, Lima BB, et al. The association of depression with adherence to antihypertensive medications : a systematic review. J Hypertens 2010;28:1785–95. doi: 10.1097/HJH.0b013e32833b4a6fLiu Q, Wang H, Liu A, et al. Adherence to prescribed antihypertensive medication among patients with depression in the United States. BMC Psychiatry 2022;22:764. doi: 10.1186/s12888-022-04424-xLiu Q, Wang H, Liu A, et al. Adherence to prescribed antihypertensive medication among patients with depression in the United States. BMC Psychiatry 2022;22:764. doi: 10.1186/s12888-022-04424-xОстроумова ОД, Парфенов ВА, Остроумова ТМ, Яхно НН, Чазова ИЕ, Боголепова АН, и др. Консенсус экспертов. Влияние антигипертензивной терапии на когнитивные функции. Системные гипертензии 2021;18:5–12. doi: 10.26442/2075082X.2021.1.200575Ostroumova O.D., Parfenov V.A., Ostroumova T.M., et al. Expert consensus. Effect of antihypertensive therapy on cognitive functions. Systemic Hypertension. 2021;18(1):5-12. (In Russ.) doi: 10.26442/2075082X.2021.1.200575Bokhour BG, Kressin NR. What Is in a Name? Circ Cardiovasc Qual Outcomes 2015;8:452–4. doi: 10.1161/CIRCOUTCOMES.114.001662Bokhour BG, Kressin NR. What Is in a Name? Circ Cardiovasc Qual Outcomes 2015;8:452–4. doi: 10.1161/CIRCOUTCOMES.114.001662Yadav AK, Budhathoki SS, Paudel M, et al. Patients understanding of their diagnosis and treatment plans during discharge in emergency ward in a tertiary care centre: A qualitative study. J Nepal Med Assoc 2019;57:357–60. doi: 10.31729/jnma.4639Yadav AK, Budhathoki SS, Paudel M, et al. Patients understanding of their diagnosis and treatment plans during discharge in emergency ward in a tertiary care centre: A qualitative study. J Nepal Med Assoc 2019;57:357–60. doi: 10.31729/jnma.4639Axon RN, Bradford WD, Egan BM. The role of individual time preferences in health behaviors among hypertensive adults: a pilot study. J Am Soc Hypertens 2009;3:35–41. doi: 10.1016/j.jash.2008.08.005Axon RN, Bradford WD, Egan BM. The role of individual time preferences in health behaviors among hypertensive adults: a pilot study. J Am Soc Hypertens 2009;3:35–41. doi: 10.1016/j.jash.2008.08.005Bradford WD. The association between individual time preferences and health maintenance habits. Med Decis Mak 2010;30:99–112. doi: 10.1177/0272989X09342276Bradford WD. The association between individual time preferences and health maintenance habits. Med Decis Mak 2010;30:99–112. doi: 10.1177/0272989X09342276Наумова ЕА, Семенова ОН. Современный взгляд на проблему приверженности пациентов к длительному лечению. Кардиология: новости, мнения, обучение 2016;2:30–9.Naumova EA, Semenova HE. A modern view of the problem of patients' adherence to long-term treatment. Cardiology: news, opinions, training 2016;2:30-9.Krousel‐Wood MA, Muntner P, Joyce CJ, et al. Adverse effects of complementary and alternative medicine on antihypertensive medication adherence: findings from the cohort study of medication adherence among older adults. J Am Geriatr Soc 2010;58:54–61. doi: 10.1111/j.1532-5415.2009.02639.xKrousel‐Wood MA, Muntner P, Joyce CJ, et al. Adverse effects of complementary and alternative medicine on antihypertensive medication adherence: findings from the cohort study of medication adherence among older adults. J Am Geriatr Soc 2010;58:54–61. doi: 10.1111/j.1532-5415.2009.02639.xShen B, Guan T, Du X, et al. Medication adherence and perceived social support of hypertensive patients in China: a community-Based Survey Study. Patient Prefer Adherence 2022;Volume 16:1257–68. doi: 10.2147/PPA.S363148Shen B, Guan T, Du X, et al. Medication adherence and perceived social support of hypertensive patients in China: a community-Based Survey Study. Patient Prefer Adherence 2022;Volume 16:1257–68. doi: 10.2147/PPA.S363148Steiner JF, Ho PM, Beaty BL, et al. Sociodemographic and clinical characteristics are not clinically useful predictors of refill adherence in patients with hypertension. Circ Cardiovasc Qual Outcomes 2009;2:451–7. doi: 10.1161/CIRCOUTCOMES.108.841635Steiner JF, Ho PM, Beaty BL, et al. Sociodemographic and clinical characteristics are not clinically useful predictors of refill adherence in patients with hypertension. Circ Cardiovasc Qual Outcomes 2009;2:451–7. doi: 10.1161/CIRCOUTCOMES.108.841635Bhusal L, Deep Pathak B, Dhakal B, et al. Determination of level of self‐reported adherence of antihypertensive drug(s) and its associated factors among patient with hypertension at a tertiary care center. J Clin Hypertens 2022;24:1444–50. doi: 10.1111/jch.14592Bhusal L, Deep Pathak B, Dhakal B, et al. Determination of level of self‐reported adherence of antihypertensive drug(s) and its associated factors among patient with hypertension at a tertiary care center. J Clin Hypertens 2022;24:1444–50. doi: 10.1111/jch.14592Pan J, Wu L, Wang H, et al. Determinants of hypertension treatment adherence among a Chinese population using the therapeutic adherence scale for hypertensive patients. Medicine (Baltimore) 2019;98:e16116. doi: 10.1097/MD.0000000000016116Pan J, Wu L, Wang H, et al. Determinants of hypertension treatment adherence among a Chinese population using the therapeutic adherence scale for hypertensive patients. Medicine (Baltimore) 2019;98:e16116. doi: 10.1097/MD.0000000000016116Li S-C. Factors affecting therapeutic compliance: A review from the patients perspective. Ther Clin Risk Manag 2008;Volume 4:269–86. doi: 10.2147/TCRM.S1458Li S-C. Factors affecting therapeutic compliance: A review from the patients perspective. Ther Clin Risk Manag 2008;Volume 4:269–86. doi: 10.2147/TCRM.S1458Бочкарева ЕВ, Бутина ЕК, Ким ИВ, Концевая АВ, Драпкина ОМ. Приверженность к антигипертензивной терапии: систематический обзор российских проспективных исследований с 2000 по 2019 гг. Рациональная Фармакотерапия в Кардиологии 2020;16:770–9. doi: 10.20996/1819-6446-2020-10-20Bochkareva E.V., Butina E.K., Kim I.V., et al. Adherence to Antihypertensive Therapy : A Systematic Review of Russian Prospective Studies from 2000 to 2019. Rational Pharmacotherapy in Cardiology. 2020;16(5):770-779. (In Russ.) doi: 10.20996/1819-6446-2020-10-20Iihara N, Tsukamoto T, Morita S, et al. Beliefs of chronically ill Japanese patients that lead to intentional non-adherence to medication. J Clin Pharm Ther 2004;29:417–24. doi: 10.1111/j.1365-2710.2004.00580.xIihara N, Tsukamoto T, Morita S, et al. Beliefs of chronically ill Japanese patients that lead to intentional non-adherence to medication. J Clin Pharm Ther 2004;29:417–24. doi: 10.1111/j.1365-2710.2004.00580.xShahin W, Kennedy GA, Stupans I. The association between social support and medication adherence in patients with hypertension: A systematic review. Pharm Pract (Granada) 2021;19:2300. doi: 10.18549/PharmPract.2021.2.2300Shahin W, Kennedy GA, Stupans I. The association between social support and medication adherence in patients with hypertension: A systematic review. Pharm Pract (Granada) 2021;19:2300. doi: 10.18549/PharmPract.2021.2.2300Huang T, Bai L, Wushouer H, et al. Clinical outcome and medical cost of originator and generic antihypertensive drugs: a population-based study in Yinzhou, China. Front Pharmacol 2022;13:1–9. doi: 10.3389/fphar.2022.757398Huang T, Bai L, Wushouer H, et al. Clinical outcome and medical cost of originator and generic antihypertensive drugs: a population-based study in Yinzhou, China. Front Pharmacol 2022;13:1–9. doi: 10.3389/fphar.2022.757398Conn VS, Ruppar TM, Chase JAD, et al. Interventions to improve medication adherence in hypertensive patients : systematic review and meta-analysis. Curr Hypertens Rep 2015;17:1–15. doi: 10.1007/s11906-015-0606-5Conn VS, Ruppar TM, Chase JAD, et al. Interventions to improve medication adherence in hypertensive patients : systematic review and meta-analysis. Curr Hypertens Rep 2015;17:1–15. doi: 10.1007/s11906-015-0606-5Pan J, Hu B, Wu L, Li Y. The Effect of Social Support on Treatment Adherence in Hypertension in China. Patient Prefer Adherence 2021;Volume 15:1953–61. doi: 10.2147/PPA.S325793Pan J, Hu B, Wu L, Li Y. The Effect of Social Support on Treatment Adherence in Hypertension in China. Patient Prefer Adherence 2021;Volume 15:1953–61. doi: 10.2147/PPA.S325793Londoño Agudelo E, Battaglioli T, Díaz Piñera A, et al. Effectiveness of a provider and patient-focused intervention to improve hypertension management and control in the primary health care setting in Cuba: a controlled before-after study. BMC Prim Care 2023;24:10. doi: 10.1186/s12875-022-01959-6Londoño Agudelo E, Battaglioli T, Díaz Piñera A, et al. Effectiveness of a provider and patient-focused intervention to improve hypertension management and control in the primary health care setting in Cuba: a controlled before-after study. BMC Prim Care 2023;24:10. doi: 10.1186/s12875-022-01959-6Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Med Pharm Reports 2019 Apr;92(2):117-122. doi: 10.15386/mpr-1201Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Med Pharm Reports 2019 Apr;92(2):117-122. doi: 10.15386/mpr-1201Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int 2015;2015:1–12. doi: 10.1155/2015/217047Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int 2015;2015:1–12. doi: 10.1155/2015/217047Meddings J, Kerr EA, Heisler M, Hofer TP. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss. BMC Health Serv Res 2012;12:270. doi: 10.1186/1472-6963-12-270Meddings J, Kerr EA, Heisler M, Hofer TP. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss. BMC Health Serv Res 2012;12:270. doi: 10.1186/1472-6963-12-270Inui TS. Improved outcomes in hypertension after physician tutorials. Ann Intern Med 1976;84:646. doi: 10.7326/0003-4819-84-6-646Inui TS. Improved outcomes in hypertension after physician tutorials. Ann Intern Med 1976;84:646. doi: 10.7326/0003-4819-84-6-646Glynn LG, Murphy AW, Smith SM, et al. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev 2010 Mar 17:(3):CD005182. doi: 10.1002/14651858.CD005182.pub4Glynn LG, Murphy AW, Smith SM, et al. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev 2010 Mar 17:(3):CD005182. doi: 10.1002/14651858.CD005182.pub4Nguyen T-M-U, Caze A La, Cottrell N. What are validated self-report adherence scales really measuring? : a systematic review. Br J Clin Pharmacol 2014;77:427–45. doi: 10.1111/bcp.12194Nguyen T-M-U, Caze A La, Cottrell N. What are validated self-report adherence scales really measuring? : a systematic review. Br J Clin Pharmacol 2014;77:427–45. doi: 10.1111/bcp.12194Hamdidouche I, Jullien V, Boutouyrie P, et al. Drug adherence in hypertension: from methodological issues to cardiovascular outcomes. J Hypertens 2017;35:1133–44. doi: 10.1097/HJH.0000000000001299Hamdidouche I, Jullien V, Boutouyrie P, et al. Drug adherence in hypertension: from methodological issues to cardiovascular outcomes. J Hypertens 2017;35:1133–44. doi: 10.1097/HJH.0000000000001299Pareja-Martínez E, Esquivel-Prados E, Martínez-Martínez F, García-Corpas JP. Questionnaires on adherence to antihypertensive treatment : a systematic review of published questionnaires and their psychometric properties. Int J Clin Pharm 2020;42:355–65. doi: 10.1007/s11096-020-00981-xPareja-Martínez E, Esquivel-Prados E, Martínez-Martínez F, García-Corpas JP. Questionnaires on adherence to antihypertensive treatment : a systematic review of published questionnaires and their psychometric properties. Int J Clin Pharm 2020;42:355–65. doi: 10.1007/s11096-020-00981-xGlasser SP, Vitolins M, Rocco MV, et al. Is medication adherence predictive of cardiovascular outcomes and blood pressure control? The systolic blood pressure intervention trial (SPRINT). Am J Hypertens 2022;35:182–91. doi: 10.1093/ajh/hpab145Glasser SP, Vitolins M, Rocco MV, et al. Is medication adherence predictive of cardiovascular outcomes and blood pressure control? The systolic blood pressure intervention trial (SPRINT). Am J Hypertens 2022;35:182–91. doi: 10.1093/ajh/hpab145Hamdidouche I, Jullien V, Boutouyrie P, et al. Routine urinary detection of antihypertensive drugs for systematic evaluation of adherence to treatment in hypertensive patients. J Hypertens 2017;35:1891–8. doi: 10.1097/HJH.0000000000001402Hamdidouche I, Jullien V, Boutouyrie P, et al. Routine urinary detection of antihypertensive drugs for systematic evaluation of adherence to treatment in hypertensive patients. J Hypertens 2017;35:1891–8. doi: 10.1097/HJH.0000000000001402Hamilton GA. Measuring adherence in a hypertension clinical trial. Eur J Cardiovasc Nurs 2003;2:219–28. doi: 10.1016/S1474-5151(03)00058-6Hamilton GA. Measuring adherence in a hypertension clinical trial. Eur J Cardiovasc Nurs 2003;2:219–28. doi: 10.1016/S1474-5151(03)00058-6Waeber B. Treatment strategy to control blood pressure optimally in hypertensive patients. Blood Press 2001;10:62–73. doi: 10.1080/08037050152112041Waeber B. Treatment strategy to control blood pressure optimally in hypertensive patients. Blood Press 2001;10:62–73. doi: 10.1080/08037050152112041Wetzels G, Nelemans P, Schouten J, et al. Electronic monitoring of adherence as a tool to improve blood pressure control a randomized controlled trial. Am J Hypertens 2007;20:119–25. doi: 10.1016/j.amjhyper.2006.07.018Wetzels G, Nelemans P, Schouten J, et al. Electronic monitoring of adherence as a tool to improve blood pressure control a randomized controlled trial. Am J Hypertens 2007;20:119–25. doi: 10.1016/j.amjhyper.2006.07.018Christensen A, Osterberg LG, Hansen EH. Electronic monitoring of patient adherence to oral antihypertensive medical treatment: a systematic review. J Hypertens 2009;27:1540–51. doi: 10.1097/HJH.0b013e32832d50efChristensen A, Osterberg LG, Hansen EH. Electronic monitoring of patient adherence to oral antihypertensive medical treatment: a systematic review. J Hypertens 2009;27:1540–51. doi: 10.1097/HJH.0b013e32832d50efHafezi H, Robertson TL, Moon GD, et al. An ingestible sensor for measuring medication adherence. IEEE Trans Biomed Eng 2015;62:99–109. doi: 10.1109/TBME.2014.2341272Hafezi H, Robertson TL, Moon GD, et al. An ingestible sensor for measuring medication adherence. IEEE Trans Biomed Eng 2015;62:99–109. doi: 10.1109/TBME.2014.2341272Naik R, Macey N, West RG, et al. First use of an ingestible sensor to manage uncontrolled blood pressure in primary practice: the UK hypertension registry. J Community Med Health Educ January 2017;7(1). doi: 10.4172/2161-0711.1000506Naik R, Macey N, West RG, et al. First use of an ingestible sensor to manage uncontrolled blood pressure in primary practice: the UK hypertension registry. J Community Med Health Educ January 2017;7(1). doi: 10.4172/2161-0711.1000506Hjørnholm U, Aamodt M, Larstorp AC, et al. Directly observed therapy in hypertension (DOT-HTN), 2018:57–85. doi: 10.1007/978-3-319-76593-8_6Hjørnholm U, Aamodt M, Larstorp AC, et al. Directly observed therapy in hypertension (DOT-HTN), 2018:57–85. doi: 10.1007/978-3-319-76593-8_6Banegas JR, Segura J, Ruilope LM, et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004;43:1338–44. doi: 10.1161/01.HYP.0000127424.59774.84Banegas JR, Segura J, Ruilope LM, et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004;43:1338–44. doi: 10.1161/01.HYP.0000127424.59774.84Peeters LEJ, Feyz L, Boersma E, et al. Clinical applicability of monitoring antihypertensive drug levels in blood. Hypertension 2020;76:80–6. doi: 10.1161/HYPERTENSIONAHA.120.15038Peeters LEJ, Feyz L, Boersma E, et al. Clinical applicability of monitoring antihypertensive drug levels in blood. Hypertension 2020;76:80–6. doi: 10.1161/HYPERTENSIONAHA.120.15038Štrauch B, Petrák O, Zelinka T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 2013;31:2455–61. doi: 10.1097/HJH.0b013e3283652c61Štrauch B, Petrák O, Zelinka T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 2013;31:2455–61. doi: 10.1097/HJH.0b013e3283652c61Hamdidouche I, Jullien V, Boutouyrie P, et al. Routine urinary detection of antihypertensive drugs for systematic evaluation of adherence to treatment in hypertensive patients. J Hypertens 2017;35:1891–8. doi: 10.1097/HJH.0000000000001402.Hamdidouche I, Jullien V, Boutouyrie P, et al. Routine urinary detection of antihypertensive drugs for systematic evaluation of adherence to treatment in hypertensive patients. J Hypertens 2017;35:1891–8. doi: 10.1097/HJH.0000000000001402.Sutherland JJ, Morrison RD, McNaughton CD, et al. Assessment of patient medication adherence, medical record accuracy, and medication blood concentrations for prescription and over-the-counter medications. JAMA Netw open 2018;1:e184196. doi: 10.1001/jamanetworkopen.2018.4196.Sutherland JJ, Morrison RD, McNaughton CD, et al. Assessment of patient medication adherence, medical record accuracy, and medication blood concentrations for prescription and over-the-counter medications. JAMA Netw open 2018;1:e184196. doi: 10.1001/jamanetworkopen.2018.4196.Gupta P, Patel P, Horne R, et al. How to screen for non-adherence to antihypertensive therapy. Curr Hypertens Rep 2016;18:89. doi: 10.1007/s11906-016-0697-7Gupta P, Patel P, Horne R, et al. How to screen for non-adherence to antihypertensive therapy. Curr Hypertens Rep 2016;18:89. doi: 10.1007/s11906-016-0697-7Агеев ФТ, Смирнова МД, Фофанова ТВ. Повышение приверженности к терапии: «дело техники»? Сердечная недостаточность 2011;4:238–43. doi: 10.1002/14651858.CD000011.pub4Ageev FT, Smirnova MD, Fofanova TV. Increasing adherence to therapy: "a matter of technique"? Heart failure 2011;4:238-43.(In Russ.)Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014;2014. doi: 10.1002/14651858.CD000011.pub4Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2014;2014. doi: 10.1002/14651858.CD000011.pub4Choudhry NK, Kronish IM, Vongpatanasin W, et al. Medication adherence and blood pressure control: a scientific statement from the American Heart Association. Hypertension 2022;79. doi: 10.1161/HYP.0000000000000203Choudhry NK, Kronish IM, Vongpatanasin W, et al. Medication adherence and blood pressure control: a scientific statement from the American Heart Association. Hypertension 2022;79. doi: 10.1161/HYP.0000000000000203Stergiou G, Brunström M, MacDonald T, et al. Bedtime dosing of antihypertensive medications : systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension. J Hypertens 2022;40:1847–58. doi: 10.1097/HJH.0000000000003240Stergiou G, Brunström M, MacDonald T, et al. Bedtime dosing of antihypertensive medications : systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension. J Hypertens 2022;40:1847–58. doi: 10.1097/HJH.0000000000003240Wallbach M, Lach N, Stock J, et al. Direct assessment of adherence and drug interactions in patients with hypertensive crisis—a cross-sectional study in the Emergency Department. J Clin Hypertens 2019;21:55–63. doi: 10.1111/jch.13448Wallbach M, Lach N, Stock J, et al. Direct assessment of adherence and drug interactions in patients with hypertensive crisis—a cross-sectional study in the Emergency Department. J Clin Hypertens 2019;21:55–63. doi: 10.1111/jch.13448Kulkarni S, Rao R, Goodman JDH, et al. Nonadherence to antihypertensive medications amongst patients with uncontrolled hypertension. Medicine (Baltimore) 2021;100:e24654. doi: 10.1097/MD.0000000000024654Kulkarni S, Rao R, Goodman JDH, et al. Nonadherence to antihypertensive medications amongst patients with uncontrolled hypertension. Medicine (Baltimore) 2021;100:e24654. doi: 10.1097/MD.0000000000024654Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296–310. doi: 10.1016/S0149-2918(01)80109-0Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296–310. doi: 10.1016/S0149-2918(01)80109-0Parati G, Kjeldsen S, Coca A, et al. Adherence to single-pill versus free-equivalent combination therapy in hypertension. Hypertension 2021;77:692–705. doi: 10.1161/HYPERTENSIONAHA.120.15781Parati G, Kjeldsen S, Coca A, et al. Adherence to single-pill versus free-equivalent combination therapy in hypertension. Hypertension 2021;77:692–705. doi: 10.1161/HYPERTENSIONAHA.120.15781Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents. Hypertension 2010;55:399–407. doi: 10.1161/HYPERTENSIONAHA.109.139816Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents. Hypertension 2010;55:399–407. doi: 10.1161/HYPERTENSIONAHA.109.139816Rea F, Savaré L, Franchi M, et al. Adherence to treatment by initial antihypertensive mono and combination therapies. Am J Hypertens 2021;34:1083–91. doi: 10.1093/ajh/hpab083Rea F, Savaré L, Franchi M, et al. Adherence to treatment by initial antihypertensive mono and combination therapies. Am J Hypertens 2021;34:1083–91. doi: 10.1093/ajh/hpab083Tsioufis K, Kreutz R, Sykara G, et al. Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature. J Hypertens 2020;38:1016–28. doi: 10.1097/HJH.0000000000002381Tsioufis K, Kreutz R, Sykara G, et al. Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature. J Hypertens 2020;38:1016–28. doi: 10.1097/HJH.0000000000002381Bramlage P, Schmidt S, Sims H. Fixed‐dose vs free‐dose combinations for the management of hypertension — an analysis of 81 958 patients. J Clin Hypertens 2018;20:705–15. doi: 10.1111/jch.13240Bramlage P, Schmidt S, Sims H. Fixed‐dose vs free‐dose combinations for the management of hypertension — an analysis of 81 958 patients. J Clin Hypertens 2018;20:705–15. doi: 10.1111/jch.13240Чазова И.Е., Жернакова Ю.В. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии 2019;16:6–31. doi: 10.26442/2075082X.2019.1.190179Chazova I.E., Zhernakova Yu.V. Diagnosis and treatment of arterial hypertension [Guidelines]. Systemic Hypertension. 2019;16(1):6-31. (In Russ.) doi: 10.26442/2075082X.2019.1.190179Артериальная гипертензия у взрослых. Клинические рекомендации 2022 2022:1–161.Arterial hypertension in adults. Clinical Guidelines 2022 2022:1–161. (In Russ.)Кисляк ОА, Жернакова ЮВ, Аксенова АВ, Чазова ИЕ. Консенсус экспертов Российского медицинского общества по артериальной гипертонии: применение фиксированных комбинаций в лечении больных артериальной гипертонией. Системные гипертензии 2024;21:5–13. doi: 10.38109/2075-082X-2024-1-5-13Kisliak O.A., Zhernakova J.V., Aksenova A.V., Chazova I.E. Russian medical society expert consensus on arterial hypertension: use of fixed combinations in the treatment of patients with arterial hypertension. Systemic Hypertension. 2024;21(1):5-13. (In Russ.) doi: 10.38109/2075-082X-2024-1-5-13Карпов ЮА, Горбунов ВМ, Логунова НА. Применение тройной фиксированной комбинации в лечении артериальной гипертензии — возможность эффективного контроля артериального давления при использовании комбинированной антигипертензивной терапии: основные результаты Российского наблюдательного исследования. Российский кардиологический журнал 2020;25:4130. doi: 10.15829/1560-4071-2020-4130Karpov Yu.A., Gorbunov V.M., Logunova N.A. Triple fixed-dose combination in the treatment of hypertension: the results of the Russian observational study TRICOLOR. Russian Journal of Cardiology. 2020;25(10):4130. (In Russ.) doi: 10.15829/1560-4071-2020-4130Du L, Cheng Z, Zhang Y, et al. The impact of fixed‐dose combination versus free‐equivalent combination therapies on adherence for hypertension: a meta‐analysis. J Clin Hypertens 2018;20:902–7. doi: 10.1111/jch.13272Du L, Cheng Z, Zhang Y, et al. The impact of fixed‐dose combination versus free‐equivalent combination therapies on adherence for hypertension: a meta‐analysis. J Clin Hypertens 2018;20:902–7. doi: 10.1111/jch.13272Sherrill B, Halpern M, Khan S, et al. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens 2011;13:898–909. doi: 10.1111/j.1751-7176.2011.00550.xSherrill B, Halpern M, Khan S, et al. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens 2011;13:898–909. doi: 10.1111/j.1751-7176.2011.00550.xMiranda RD, Mion D, Rocha JC, et al. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: The assessment of combination therapy of amlodipine/ramipril (ATAR) study. Clin Ther 2008;30:1618–28. doi: 10.1016/j.clinthera.2008.09.008Miranda RD, Mion D, Rocha JC, et al. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: The assessment of combination therapy of amlodipine/ramipril (ATAR) study. Clin Ther 2008;30:1618–28. doi: 10.1016/j.clinthera.2008.09.008Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007;21:220–4. doi: 10.1038/sj.jhh.1002140Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007;21:220–4. doi: 10.1038/sj.jhh.1002140Марцевич СЮ, Кутишенко НП, Лукина ЮВ, Драпкина ОМ. Полифармация: определение, влияние на исходы,необходимость коррекции. Рациональная фармакотерапия в кардиологии 2023;19:254–63. doi: 10.20996/1819-6446-2023-2924Martsevich S.Yu., Kutishenko N.P., Lukina Yu.V., Drapkina O.M. Polypharmacy: definition, impact on outcomes, need for correction. Rational Pharmacotherapy in Cardiology. 2023;19(3):254-263. (In Russ.) doi: 10.20996/1819-6446-2023-2924Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med 2022;387:967–77. doi: 10.1056/NEJMoa2208275Castellano JM, Pocock SJ, Bhatt DL, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med 2022;387:967–77. doi: 10.1056/NEJMoa2208275Castellano JM, Sanz G, Peñalvo JL, et al. A polypill strategy to improve adherence. J Am Coll Cardiol 2014;64:2071–82. doi: 10.1016/j.jacc.2014.08.021Castellano JM, Sanz G, Peñalvo JL, et al. A polypill strategy to improve adherence. J Am Coll Cardiol 2014;64:2071–82. doi: 10.1016/j.jacc.2014.08.021Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014;348:g3318–g3318. doi: 10.1136/bmj.g3318Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014;348:g3318–g3318. doi: 10.1136/bmj.g3318Thom S. Effects of a fixed-dose combination strategy on aadherence and risk factors in patients with or at high risk of CVD. JAMA 2013;310:918. doi: 10.1001/jama.2013.277064Thom S. Effects of a fixed-dose combination strategy on aadherence and risk factors in patients with or at high risk of CVD. JAMA 2013;310:918. doi: 10.1001/jama.2013.277064Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet 2021;398:1133–46. doi: 10.1016/S0140-6736(21)01827-4Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet 2021;398:1133–46. doi: 10.1016/S0140-6736(21)01827-4Mahmood S, Jalal Z, Abdul Hadi M, et al. Non-adherence to prescribed antihypertensives in primary, secondary and tertiary healthcare settings in islamabad, Pakistan: a cross-sectional study. Patient Prefer Adherence 2020;Volume 14:73–85. doi: 10.2147/PPA.S235517Mahmood S, Jalal Z, Abdul Hadi M, et al. Non-adherence to prescribed antihypertensives in primary, secondary and tertiary healthcare settings in islamabad, Pakistan: a cross-sectional study. Patient Prefer Adherence 2020;Volume 14:73–85. doi: 10.2147/PPA.S235517Law MR. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427–0. doi: 10.1136/bmj.326.7404.1427Law MR. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326:1427–0. doi: 10.1136/bmj.326.7404.1427Алексеева ТА, Литвин АЮ, Елфимова ЕМ, и др. Consensus of experts from the Russian Medical Society of Arterial Hypertension. Arterial hypertension and erectile dysfunction. Системные гипертензии 2021;18:69–79. doi: 10.26442/2075082X.2021.2.200836Alekseeva T.A., Litvin A.Yu., Elfimova E.M., et al. Consensus of experts from the Russian Medical Society of Arterial Hypertension. Arterial hypertension and erectile dysfunction. Systemic Hypertension. 2021;18(2):69-79. (In Russ.) doi: 10.26442/2075082X.2021.2.200836Akasaki Y, Kubozono T, Higuchi K, Ohishi M. Relationships between anti-hypertensive drugs and nocturia : a systematic review. J Hypertens 2021;39:e48. doi: 10.1097/01.hjh.0000744868.03766.48Akasaki Y, Kubozono T, Higuchi K, Ohishi M. Relationships between anti-hypertensive drugs and nocturia : a systematic review. J Hypertens 2021;39:e48. doi: 10.1097/01.hjh.0000744868.03766.48Liang L, Kung JY, Mitchelmore B, et al. Comparative peripheral edema for dihydropyridines calcium channel blockers treatment : a systematic review and network meta‐analysis. J Clin Hypertens 2022;24:536–54. doi: 10.1111/jch.14436Liang L, Kung JY, Mitchelmore B, et al. Comparative peripheral edema for dihydropyridines calcium channel blockers treatment : a systematic review and network meta‐analysis. J Clin Hypertens 2022;24:536–54. doi: 10.1111/jch.14436Fusco N, Sils B, Graff JS, et al. Cost-sharing and adherence, clinical outcomes, health care utilization, and costs : a systematic literature review. J Manag Care Spec Pharm 2023;29:4–16. doi: 10.18553/jmcp.2022.21270Fusco N, Sils B, Graff JS, et al. Cost-sharing and adherence, clinical outcomes, health care utilization, and costs : a systematic literature review. J Manag Care Spec Pharm 2023;29:4–16. doi: 10.18553/jmcp.2022.21270Cooper-DeHoff RM, Elliott WJ. Generic drugs for hypertension: Are they really equivalent? Curr Hypertens Rep 2013;15:340–5. doi: 10.1007/s11906-013-0353-4Cooper-DeHoff RM, Elliott WJ. Generic drugs for hypertension: Are they really equivalent? Curr Hypertens Rep 2013;15:340–5. doi: 10.1007/s11906-013-0353-4Dinic M, Maillard N, Bouillet M, et al. Generic vs. brand-name drugs for the treatment of hypertension. Arch Cardiovasc Dis Suppl 2019;11:e373. doi: 10.1016/j.acvdsp.2019.05.100Dinic M, Maillard N, Bouillet M, et al. Generic vs. brand-name drugs for the treatment of hypertension. Arch Cardiovasc Dis Suppl 2019;11:e373. doi: 10.1016/j.acvdsp.2019.05.100Corrao G, Soranna D, La Vecchia C, et al. Medication persistence and the use of generic and brandname blood pressure-lowering agents. J Hypertens 2014;32:1146–53. doi: 10.1097/HJH.0000000000000130Corrao G, Soranna D, La Vecchia C, et al. Medication persistence and the use of generic and brandname blood pressure-lowering agents. J Hypertens 2014;32:1146–53. doi: 10.1097/HJH.0000000000000130Ryan D, Carr A. A study of the differential effects of Tomm’s questioning styles on therapeutic alliance. Fam Process 2001;40:67–77. doi: 10.1111/j.1545-5300.2001.4010100067.xRyan D, Carr A. A study of the differential effects of Tomm’s questioning styles on therapeutic alliance. Fam Process 2001;40:67–77. doi: 10.1111/j.1545-5300.2001.4010100067.xThakkar J, Kurup R, Laba T-L, et al. Mobile telephone text messaging for medication adherence in chronic disease. JAMA Intern Med 2016;176:340. doi: 10.1001/jamainternmed.2015.7667Thakkar J, Kurup R, Laba T-L, et al. Mobile telephone text messaging for medication adherence in chronic disease. JAMA Intern Med 2016;176:340. doi: 10.1001/jamainternmed.2015.7667Лукина Ю.В., Кутишенко Н.П., Марцевич С.Ю., и др. Методические рекомендации: «Приверженность к лекарственной терапии у больных хроническими неинфекционными заболеваниями. Решение проблемы в ряде клинических ситуаций». Профилактическая Медицина 2020;23(3):2042-2060. doi: 10.17116/profmed20202303242Lukina Yu.V., Kutishenko N.P., Martsevich S.Yu., et al. Methodological recommendations: &quot;Adherence to drug therapy in patients with chronic non-communicable diseases. Addressing the problem in a number of clinical situations&quot;. Russian Journal of Preventive Medicine. 2020;23(3-2):42-60. (In Russ.) doi: 10.17116/profmed20202303242Фофанова ТВ, Агеев ФТ, Смирнова МД, Деев АД. Приверженность к терапии в амбулаторных условиях: возможность выявления и оценка эффективности терапии. Кардиология 2017;57:35–42. doi: 10.18087/cardio.2017.7.10004Fofanova T.V., Ageev F.T., Smirnova M.D., Deev A.D. Adherence to Therapy in the Outpatient Setting: the Ability to Identify and Assess the Effectiveness of Therapy. Kardiologiia. 2017;57(7):35-42. (In Russ.) doi: 10.18087/cardio.2017.7.10004Агеев Ф.Т., Фофанова Т.В., Смирнова М.Д., и др. Методы технического воздействия как фактор повышения приверженности терапии больных сердечно-сосудистыми заболеваниями в амбулаторной практике. Итоги годичного наблюдения. Кардиоваскулярная терапия и профилактика 2012;11:36–41. doi: 10.15829/1728-8800-2012-4-36-41Ageev F.T., Fofanova T.V., Smirnova M.D., et al. Technology-based methods in the improvement of therapy compliance among ambulatory cardiac patients: one-year follow-up data. Cardiovascular Therapy and Prevention. 2012;11(4):36-41. (In Russ.) doi: 10.15829/1728-8800-2012-4-36-41Fletcher BR, Hartmann-Boyce J, Hinton L, McManus RJ. The effect of self-monitoring of blood pressure on medication adherence and ifestyle factors: a systematic review and meta-analysis. Am J Hypertens 2015;28:1209–21. doi: 10.1093/ajh/hpv008Fletcher BR, Hartmann-Boyce J, Hinton L, McManus RJ. The effect of self-monitoring of blood pressure on medication adherence and ifestyle factors: a systematic review and meta-analysis. Am J Hypertens 2015;28:1209–21. doi: 10.1093/ajh/hpv008Stergiou GS, Palatini P, Parati G, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens 2021;39:1293–302. doi: 10.1097/HJH.0000000000002843Stergiou GS, Palatini P, Parati G, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens 2021;39:1293–302. doi: 10.1097/HJH.0000000000002843Солнцева Т.Д., Сивакова О.А., Чазова И.Е. От пальпации пульса до безманжетного измерения: эволюция способов определения артериального давления. Терапевтический архив 2021;93:526–31. doi: 10.26442/00403660.2021.04.200690Solnceva TD, Sivakova OA, Chazova IE. From palpation of the pulse to cuff-free methods: evolution of arterial pressure measurement methods. Terapevticheskii arkhiv 2021;93(4):526-531. (In Russ.) doi: 10.26442/00403660.2021.04.200690Бойцов СА, Иванова ГЕ, Рогоза АН, и др. Анализ методов и технических решений для измерения артериального давления с применением телемедицинских технологий при кардиологических исследованиях в процессе медицинской реабилитации. Вестник воостановительной медицины 2018;6:91–5.Boytsov SA, Ivanova GE, Rogoza AN, et al. Analysis of methods and technical solutions for measuring blood pressure using telemedicine and cluster technologies in cardiac research during medical rehabilitation. Bulletin of Rehabilitation Medicine 2018;17(6):91-95.Schneider MP, Burnier M. Partnership between patients and interprofessional healthcare providers along the multifaceted journey to medication adherence. Br J Clin Pharmacol 2023;89:1992–5. doi: 10.1111/bcp.15325Schneider MP, Burnier M. Partnership between patients and interprofessional healthcare providers along the multifaceted journey to medication adherence. Br J Clin Pharmacol 2023;89:1992–5. doi: 10.1111/bcp.15325Fuller RH, Perel P, Navarro-Ruan T, et al. Improving medication adherence in patients with cardiovascular disease : a systematic review. Heart 2018;104:1238–43. doi: 10.1136/heartjnl-2017-312571Fuller RH, Perel P, Navarro-Ruan T, et al. Improving medication adherence in patients with cardiovascular disease : a systematic review. Heart 2018;104:1238–43. doi: 10.1136/heartjnl-2017-312571Proia KK, Thota AB, Njie GJ, et al. Team-based care and improved blood pressure control. Am J Prev Med 2014;47:86–99. doi: 10.1016/j.amepre.2014.03.004Proia KK, Thota AB, Njie GJ, et al. Team-based care and improved blood pressure control. Am J Prev Med 2014;47:86–99. doi: 10.1016/j.amepre.2014.03.004Baker D, Roberts D, Newcombe R, Fox K. Evaluation of drug information for cardiology patients. Br J Clin Pharmacol 1991;31:525–31. doi: 10.1111/j.1365-2125.1991.tb05574.xBaker D, Roberts D, Newcombe R, Fox K. Evaluation of drug information for cardiology patients. Br J Clin Pharmacol 1991;31:525–31. doi: 10.1111/j.1365-2125.1991.tb05574.xUkoha-Kalu BO, Isah A, Biambo AA, et al. Effectiveness of educational interventions on hypertensive patients’ self-management behaviours: an umbrella review protocol. BMJ Open 2023;13:e073682. doi: 10.1136/bmjopen-2023-073682Ukoha-Kalu BO, Isah A, Biambo AA, et al. Effectiveness of educational interventions on hypertensive patients’ self-management behaviours: an umbrella review protocol. BMJ Open 2023;13:e073682. doi: 10.1136/bmjopen-2023-073682Чазова И.Е., Агеев Ф.Т., Фофанова Т.В., и др. Обучение и самообразование пациента – важный шаг на пути повышения приверженности пациента лечению. Системные гипертензии 2014;3:7–10.Chazova I.Ye., Ageev F.T., Fofanova T.V., et al. Education and self-education of the patients is an important step towards increasing patients acceptance of therapy. Systemic Hypertension. 2014;11(3):7-10.Naik AD, Kallen MA, Walder A, Street RL. Improving hypertension control in diabetes mellitus. Circulation 2008;117:1361–8. doi: 10.1161/CIRCULATIONAHA.107.724005Naik AD, Kallen MA, Walder A, Street RL. Improving hypertension control in diabetes mellitus. Circulation 2008;117:1361–8. doi: 10.1161/CIRCULATIONAHA.107.724005Lindenfeld J, Jessup M. ‘Drugs don’t work in patients who don’t take them’ (C. Everett Koop, MD, US Surgeon General, 1985). Eur J Heart Fail 2017;19:1412–3. doi: 10.1002/ejhf.920Lindenfeld J, Jessup M. ‘Drugs don’t work in patients who don’t take them’ (C. Everett Koop, MD, US Surgeon General, 1985). Eur J Heart Fail 2017;19:1412–3. doi: 10.1002/ejhf.920

The authors declare that there are no conflicts of interest present.